2021
Basal Ganglia Calcification Is Associated With Local and Systemic Metabolic Mechanisms in Adult Hypoparathyroidism
Zavatta G, Tebben P, McCollough C, Yu L, Vrieze T, Clarke B. Basal Ganglia Calcification Is Associated With Local and Systemic Metabolic Mechanisms in Adult Hypoparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2021, 106: 1900-1917. PMID: 33788935, DOI: 10.1210/clinem/dgab162.Peer-Reviewed Original ResearchConceptsLow serum calciumBasal ganglia calcificationSerum calciumChronic hypoparathyroidismNonsurgical patientsSerum phosphorusAssociated with lower serum calciumComputed tomographyDecreased serum parathyroid hormoneRetrospective review of medical recordsReview of medical recordsSerum parathyroid hormoneAssociated with soft tissue calcificationSex-matched controlsAssociated with greater volumeDuration of treatmentCase-control studyDistribution of calcificationSoft tissue calcificationIncreased serum phosphorusCalcium/phosphate ratioCT headRetrospective reviewParathyroid hormoneImaging findings
2016
Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect
O’Keeffe D, Tebben P, Kumar R, Singh R, Wu Y, Wermers R. Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect. Osteoporosis International 2016, 27: 3121-3125. PMID: 27129455, DOI: 10.1007/s00198-016-3615-6.Peer-Reviewed Original ResearchConceptsMonoallelic mutationsGene dose effectCYP24A1 mutationsCYP24A1 geneBiallelic mutationsBiochemical phenotypeDisease manifestationsElevated serum 1,25(OH)2DBone turnover markersMutations of CYP24A1Dose effectCompound heterozygous mutationsVitamin D metabolitesLow PTH concentrationsSerum 1,25(OH)2DUrine calciumResultsThe probandTurnover markersUrinary calciumHeterozygous mutationsPTH concentrationsD metabolitesSequence informationIntroductionThe objectiveMedical history
2013
Clinical spectrum of hypophosphatasia diagnosed in adults
Berkseth K, Tebben P, Drake M, Hefferan T, Jewison D, Wermers R. Clinical spectrum of hypophosphatasia diagnosed in adults. Bone 2013, 54: 21-27. PMID: 23352924, DOI: 10.1016/j.bone.2013.01.024.Peer-Reviewed Original ResearchConceptsMusculoskeletal painAbsence of genetic testingUrine phosphoethanolamineHistory of fractureAdult hypophosphatasiaHip/femoral neckClinical manifestationsClinical spectrum of hypophosphatasiaSubtrochanteric femur fracturesIncident fracturesLow serum alkaline phosphataseDiagnostic codesIliac crest bone biopsiesAlkaline phosphataseFracture patientsFamily historyConsistent with osteomalaciaEvidence of osteomalaciaInclusion criteriaGenetic testingFemur fracturesMedical recordsSerum alkaline phosphataseSymptomatic subjectsRadiographic chondrocalcinosis
2006
Oncogenic Osteomalacia: Localization of Underlying Peripheral Mesenchymal Tumors with Use of Tc 99m Sestamibi Scintigraphy
Hodgson S, Clarke B, Tebben P, Mullan B, Cooney W, Shives T. Oncogenic Osteomalacia: Localization of Underlying Peripheral Mesenchymal Tumors with Use of Tc 99m Sestamibi Scintigraphy. Endocrine Practice 2006, 12: 35-42. PMID: 16524861, DOI: 10.4158/ep.12.1.35.Peer-Reviewed Original ResearchConceptsTc-99m sestamibi scanM sestamibi scanMesenchymal tumorsTc-99m sestamibi scintigraphyM sestamibi scintigraphyCost-effective initial strategyOncogenic osteomalaciaTherapeutic failureComplete resolutionCase reportD concentrationsNeoplasmsTumorTissue compartmentsOsteomalaciaAlternative localization technique
2005
Elevated fibroblast growth factor 23 in women with malignant ovarian tumors.
Tebben P, Kalli K, Cliby W, Hartmann L, Grande J, Singh R, Kumar R. Elevated fibroblast growth factor 23 in women with malignant ovarian tumors. Mayo Clinic Proceedings 2005, 80: 745-51. PMID: 15948297, DOI: 10.1016/s0025-6196(11)61528-0.Peer-Reviewed Original ResearchConceptsAdvanced-stage ovarian cancerEarly-stage ovarian cancerOvarian cancerFGF23 concentrationsPlasma FGF23 concentrationCFGF23 concentrationsSerum iFGF23Ovarian tumorsHealthy womenMalignant ovarian cancer cellsMalignant ovarian tumorsBenign ovarian tumorsAdvanced-stage diseaseAdvanced-stage tumorsFibroblast growth factor 23Elevated fibroblast growth factorOvarian cancer cellsSerum phosphate concentrationStage of diseaseSerum FGF23 concentrationsOvarian massBenign diseaseSerum phosphorusBenign massesMayo Clinic
2004
Fibroblast Growth Factor 23, Parathyroid Hormone, and 1α,25-Dihydroxyvitamin D in Surgically Treated Primary Hyperparathyroidism
Tebben P, Singh R, Clarke B, Kumar R. Fibroblast Growth Factor 23, Parathyroid Hormone, and 1α,25-Dihydroxyvitamin D in Surgically Treated Primary Hyperparathyroidism. Mayo Clinic Proceedings 2004, 79: 1508-1513. PMID: 15595334, DOI: 10.4065/79.12.1508.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersDihydroxycholecalciferolsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFollow-Up StudiesHumansHyperparathyroidismMaleMiddle AgedParathyroid GlandsParathyroid HormoneParathyroidectomyPostoperative CarePreoperative CareProbabilityProspective StudiesSampling StudiesSensitivity and SpecificitySeverity of Illness IndexStatistics, NonparametricTreatment OutcomeConceptsBone-specific alkaline phosphataseBone-specific alkaline phosphatase concentrationsFibroblast growth factor 23Primary hyperparathyroidismParathyroid hormoneSerum phosphorus concentrationFGF23 concentrationsSerum calciumSurgically treated primary hyperparathyroidismElevated serum calciumLow-normal rangeParathyroid hormone concentrationsAdult patientsPreoperative stateSerum phosphorusPostoperative stateHyperparathyroidismHealthy controlsFibroblast growth factorPatientsFGF23Growth factorSurgerySerumPhosphorus homeostasis